BTL Industries v. Dr. Devs Plastic Surgery: Consent Judgment & Permanent Injunction
BTL Industries, Inc. brought a four-patent infringement action against a New Jersey medical spa and its affiliates over proprietary magnetic stimulation technology used in aesthetic body treatments. The parties reached a negotiated resolution, with the court entering a consent judgment and permanent injunction — concluding the case in under 300 days.
Magnetic stimulation IP enforcement ends in permanent injunction
BTL Industries, Inc., the plaintiff, filed this patent infringement action on 10 November 2022 in the U.S. District Court for the District of New Jersey. The defendants — Dr. Devs Plastic Surgery & Medspa, LLC, 1800 Drs. Diet LLC, and individual Baldev Sandhu — were alleged to have infringed four BTL patents covering aesthetic magnetic stimulation and biological structure treatment methods: US10478634B2, US10695575B1, US9636519B2, and US11266852B2.
The recorded basis of termination is Injunction Granted. The docket order reflects a joint motion by all parties requesting the court to enter a consent judgment and permanent injunction, with the defendants stipulating and consenting to each provision. The parties stated they had agreed to terms and conditions representing a negotiated resolution; the specific terms beyond the injunction itself are not disclosed in the available record.
The case closed on 24 August 2023 — 287 days after filing — without proceeding to claim construction or trial. The swift resolution, combined with the defendants' explicit stipulation to every provision of the consent judgment, suggests BTL's enforcement position was strong enough to compel agreement at an early stage. What commercial arrangements, if any, accompany the injunction are not disclosed in the public record.
See Complete Case & Patent Analysis →Filing to Injunction Granted in 287 days
287 days from filing to close — resolved well within typical district court patent trial timelines
US10478634B2 — Aesthetic biological structure treatment by magnetic field
Any company developing, distributing, or deploying electromagnetic or magnetic stimulation devices for aesthetic or therapeutic body treatment — including neuromuscular stimulation, body-contouring, or non-invasive fat reduction platforms — should assess FTO exposure against US10478634B2, US10695575B1, US9636519B2, and US11266852B2. This case confirms that BTL actively enforces this portfolio at the clinic operator level, not only against device manufacturers, making the risk surface broader than typically assumed.
Official order — verbatim text
The joint motion recites that all defendants — Dr. Devs Plastic Surgery & Medspa, LLC, 1800 Drs. Diet LLC, and Baldev Sandhu — stipulated and consented to the consent judgment and permanent injunction and to each and every provision therein. This express multi-defendant stipulation, covering all four asserted patents, represents a comprehensive resolution of the infringement claims without a merits adjudication at trial. The specific negotiated terms and conditions referenced by the parties are not disclosed in the available record.
Consent judgment: what the agreed resolution means for both parties
A court-entered judgment binding on all defendants
A consent judgment is a binding, court-entered judgment reflecting terms agreed by the parties. Unlike a voluntary dismissal, it carries the full force of a court order and is enforceable as such. Here, the defendants expressly stipulated to the judgment and permanent injunction, meaning the court retains authority to enforce compliance directly — without the need for fresh litigation to establish liability.
Binding & court-enforcedBTL secures a permanent injunction across all four patents
BTL Industries obtained what patent holders most often seek in medical device enforcement: a permanent injunction barring the defendants from continuing the alleged infringing activity. With all four asserted patents now backed by a court order, BTL strengthens its enforcement posture in the aesthetic magnetic stimulation market. The consent judgment also establishes a clear precedent for future enforcement against similarly situated actors.
Injunction securedDefendants stipulate to injunction and all terms of judgment
Dr. Devs Plastic Surgery & Medspa, LLC, 1800 Drs. Diet LLC, and Baldev Sandhu each consented to the judgment and permanent injunction. By stipulating to every provision, the defendants accepted the court order without a merits determination at trial. Any breach of the injunction would expose them to contempt proceedings. The specific terms and conditions of the negotiated resolution beyond the injunction itself are not disclosed in the available record.
Injunction accepted by all defendantsMagnetic stimulation device IP: enforcement signal for the medspa sector
This outcome signals that BTL Industries actively monitors and enforces its magnetic stimulation patent portfolio against smaller aesthetic clinic operators. Medical spas and wellness centres deploying body-contouring or neuromuscular stimulation devices should treat this consent judgment as a prompt to conduct FTO analysis against BTL's portfolio. The inclusion of an individual defendant (Baldev Sandhu) also demonstrates that enforcement can extend beyond the corporate entity.
High enforcement risk in medspa sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BTL Industries, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Dr. Devs Plastic Surgery & Medspa, LLC | Company | /Search in Eureka ↗ |
| Co-Defendant | 1800 Drs. Diet LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Baldev Sandhu | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Lestin L. Kenton , Jr. | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne, Kessler, Goldstein & Fox, PLLC | Law Firm | Representing BTL Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | David L. Hecht | Attorney | Counsel for Dr. Devs Plastic Surgery & Medspa, LLCSearch in Eureka ↗ |
| Defendant law firm | Hecht Partiners LLP | Law Firm | Representing Dr. Devs Plastic Surgery & Medspa, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the aesthetic magnetic stimulation IP space
Forward-looking patent and innovation intelligence derived from BTL Industries' enforcement of its magnetic stimulation portfolio against aesthetic clinic operators in New Jersey.
BTL's magnetic stimulation portfolio: continuation depth and coverage
The four asserted patents stem from at least three distinct application chains, suggesting BTL has pursued a continuation strategy to maintain broad and layered claim coverage across device hardware and method claims. Monitoring BTL's pending applications in this family could reveal where the company is seeking to extend protection next — particularly into software control, waveform optimisation, or multi-tissue targeting.
Portfolio depth signalFiling trends in non-invasive electromagnetic body treatment
The aesthetic electromagnetic stimulation space — covering focused HIFEM, pulsed magnetic field therapy, and neuromuscular activation — has seen growing patent filings from both large device companies and emerging startups. Tracking filing velocity and claim focus across this landscape helps identify which players are building IP positions that could challenge or complement BTL's existing coverage.
Crowded technology areaSmall clinic operators: IP exposure in the aesthetic device supply chain
Dr. Devs Plastic Surgery and its affiliates held no evident patent assets in this dispute. This asymmetry — a well-resourced patent holder versus device-using clinic operators — is increasingly common in the aesthetics sector. Device distributors and equipment lessors supplying magnetic stimulation platforms to medspas should assess whether their supply agreements include indemnification against downstream enforcement actions of this type.
Asymmetric IP exposureAdjacent R&D space: personalised waveform and AI-guided stimulation protocols
BTL's asserted patents focus on magnetic field methods and device configurations for biological structure treatment. Adjacent innovation areas — including adaptive waveform generation, AI-guided treatment planning, and multi-modal aesthetic stimulation combining RF and magnetic energy — may represent white space where new IP could be established. Early filers in these adjacent claims could build differentiated positions outside BTL's current claim scope.
Adjacent innovation white spaceSimilar patent cases: aesthetic device & magnetic stimulation enforcement
Explore related patent infringement actions involving magnetic stimulation, aesthetic medical devices, and non-invasive body treatment IP litigated in U.S. district courts.
What this case signals for the aesthetic device IP landscape
BTL's four-patent enforcement action and rapid injunction highlights the commercial stakes of magnetic stimulation IP in the fast-growing aesthetics market.
BTL is an active enforcer — medspa operators face real injunction risk
This case demonstrates BTL Industries' willingness to pursue patent enforcement actions against individual clinic operators, not just large device manufacturers. Any medspa or aesthetic clinic deploying electromagnetic body treatment devices should proactively assess FTO exposure against BTL's growing patent portfolio before deploying such technology commercially.
Four-patent assertion raises the bar for design-arounds
With four distinct granted patents asserted — spanning stimulation methods and device configurations — designing around a single claim family is unlikely to resolve infringement risk. Competitors and device distributors operating in the magnetic stimulation aesthetics space should conduct claim-by-claim analysis across all four asserted patents to identify viable non-infringing alternatives.
BTL v Dr. — key questions answered
The case resolved by consent judgment and permanent injunction. The recorded basis of termination is Injunction Granted. All defendants — Dr. Devs Plastic Surgery & Medspa LLC, 1800 Drs. Diet LLC, and Baldev Sandhu — stipulated and consented to the judgment. The specific negotiated terms and conditions are not disclosed in the available public record.
BTL Industries asserted four patents: US10478634B2, US10695575B1, US9636519B2, and US11266852B2. These cover aesthetic methods of treating biological structures by magnetic field and magnetic stimulation methods and devices for therapeutic treatments.
The permanent injunction, entered as part of the consent judgment, is a binding court order that the defendants expressly stipulated to. It bars the defendants from continuing the alleged infringing activity. Any breach would expose the defendants — including individual defendant Baldev Sandhu — to contempt of court proceedings enforceable by the District of New Jersey.
The case was filed on 10 November 2022 and closed on 24 August 2023 — a total of 287 days. The case resolved before proceeding to claim construction or trial, consistent with early-stage negotiated resolution following the filing of the infringement complaint.
Yes. The consent judgment confirms BTL actively enforces US10478634B2, US10695575B1, US9636519B2, and US11266852B2 against clinic-level operators of aesthetic magnetic stimulation equipment, not only device manufacturers. Companies distributing or deploying such devices commercially should conduct claim-specific FTO analysis across all four patents and monitor BTL's continuation filings in these application families.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.